Importance of the pharmacokinetics of valproic acid in an individualized approach to the treatment of epileptic women of fertile age

被引：0
作者：
Shnaider N.A. [1 ]
Sychev D.A. [2 ]
Pilyugina M.S. [1 ]
Dmitrenko D.V. [1 ]
Bochanova E.N. [1 ]
机构：
[1] V. F. Voino-Yasenetskii Krasnoyarsk State Medical University,
[2] I. M. Sechenov First Moscow State Medical University,undefined
来源：
Neuroscience and Behavioral Physiology | 2012年 / 42卷 / 9期
基金：
中国国家自然科学基金;
关键词：
Epilepsy; Folic acid antagonist; Pharmacokinetics; Valproic acid; Women;
D O I：
10.1007/s11055-012-9663-2
中图分类号：
学科分类号：
摘要：
A clinical case of the development of therapeutic side effects in an epileptic woman of childbearing age is presented. The development of therapeutic side effects occurred on the background of an intermediate therapeutic dose of a valproic acid formulation and was associated with primary (idiopathic) and secondary (valproate-induced) impairments to the folate cycle on the background of a combination of a polymorphism in the CYP2C9*3 gene and a mutation in the MTHFR gene. © 2012 Springer Science+Business Media New York.
引用
收藏
页码：963 / 968
页数：5
相关论文
共 24 条
  • [11] Shnaider N.A., Pilyugina M.S., Dmitrenko D.V., Et Al., The frequency of adverse drug reactions on the background of use of anticonvulsants in epilepsy patients, Klin. Farmakol. Ter., 6, pp. 180-184, (2010)
  • [12] Aspinall M.G., Hamermesh R.G., Realizing the promise of personalized medicine, Harv. Bus. Rev., 85, 10, pp. 108-117, (2007)
  • [13] Brooks M., Valproic acid in pregnancy linked to several congenital malformations, New Engl. J. Med., 362, pp. 2185-2193, (2010)
  • [14] Finan J.E., Zhao R.Y., From molecular diagnostics to personalized testing, Pharmacogenomics, 8, 1, pp. 85-99, (2007)
  • [15] Giovanucci E., Chen J., Smith-Warner S.A., Et Al., Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas, Cancer Epidemiol. Biomarkers Prev., 12, 10, pp. 970-979, (2003)
  • [16] Gueant-Rodriguez R.M., Rendeli C., Namour B., Et Al., Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans, Neurosci. Lett., 334, 3, pp. 189-192, (2003)
  • [17] Kirke P.N., Mills J.L., Molloy A.M., Et Al., Impact of the MTHFR C677T polymorphism on risk of neural tube defects: Case-control study, Brit. Med. J., 328, 7455, pp. 1535-1536, (2004)
  • [18] Kluijtmans L.A., Van Den Heuvel L.P., Boers G.H., Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene, is a genetic risk factor for cardiovascular disease, Am. J. Hum. Genet., 58, 1, pp. 35-41, (1996)
  • [19] Matok I., Gorodisher R., Koren G., Et Al., Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations, Brit. J. Clin. Pharmacol., 68, 6, pp. 956-962, (2009)
  • [20] Pilotto A., Seripa D., Franceschi M., Et Al., Genetic susceptibility to non-steroidal anti-inflammatory drug-related gastroduodenal bleeding: Role of cytochrome P450 2C9 polymorphisms, Gastroenterology, 133, 2, pp. 465-471, (2007)
123